8-K: Modular Medical Secures $3.7M Through Warrant Inducement

Modular Medical, Inc. announced it will receive approximately $3.7 million in gross proceeds by inducing holders of existing warrants to exercise at a reduced price, issuing new warrants in return.

Summary

• Entered into inducement offer letter agreements on September 22, 2025, with holders of 2023 and 2025 Warrants.
• Holders of 1,519,200 shares from 2023 Warrants (original exercise price $1.22) and 3,975,428 shares from 2025 Warrants (original exercise price $1.12) agreed to exercise.
• The exercise price for these warrants was reduced to $0.68 per share, a 10% discount to the Nasdaq Official Closing Price of $0.7611 on September 19, 2025.
• This transaction is expected to generate approximately $3.7 million in gross proceeds.
• In consideration, new unregistered common stock purchase warrants (New Warrants) will be issued to acquire approximately 2,747,314 shares (50% of the exercised outstanding warrants).
• The New Warrants will have an exercise price of $0.84 per share, a 10% premium to the Nasdaq Official Closing Price of $0.7611 on September 19, 2025, and a 5-year term.
• Newbridge Securities Corporation acted as the servicing agent and will receive a fixed fee of $400,000 plus up to $50,000 in expense reimbursement.
• The transaction is expected to close on or about September 25, 2025.

Sentiment

Score: 6

Explanation: The capital raise provides immediate liquidity, which is positive for the company's operations. However, the terms involve significant dilution from the discounted exercise of existing warrants and the issuance of new warrants, which is a negative for existing shareholders. It's a necessary but costly financing event.

Positives

• Secured approximately $3.7 million in gross proceeds, providing immediate capital.
• Reduced the number of outstanding warrants with lower exercise prices, converting them into common stock.
• New warrants issued at a 10% premium to the recent closing price, indicating a higher future exercise price.

Negatives

• Existing warrant holders exercised their warrants at a significantly reduced price ($0.68 per share) compared to their original exercise prices ($1.22 and $1.12), resulting in less capital raised per share than originally anticipated.
• Issuance of new warrants (2,747,314 shares) represents future potential dilution for existing shareholders.
• Paid a fixed fee of $400,000 and up to $50,000 in expense reimbursement to Newbridge Securities Corporation.

Risks

• The New Warrants will have extremely limited liquidity as there is no established trading market and no intention to list them on any exchange.
• Future exercise of the New Warrants will lead to further dilution of common stock.
• Must comply with Nasdaq Rule 5635(d) regarding the Maximum Issuance Amount (not exceeding 19.99% of outstanding common stock prior to issuance) for shares issued at an adjusted price.
• Expects to enter into further Warrant Letters, which could lead to additional dilution and fees.

Future Outlook

The company expects to enter into further Warrant Letters prior to the Closing Date and will release additional disclosure regarding the final amounts of outstanding warrants exercised and new warrants issued. The company will use commercially reasonable efforts to register the resale of the shares of common stock underlying the New Warrants.

Management Comments

• The company, by countersigning the inducement letters, agreed to adjust the exercise price of the 2023 and 2025 Warrants.

Industry Context

This transaction represents a common strategy for companies to raise capital by incentivizing existing warrant holders to exercise, particularly when the market price of the stock falls below the original warrant exercise price. It provides immediate liquidity but often comes with the cost of dilution and reduced per-share proceeds compared to the original terms. The issuance of new warrants with a higher exercise price and a longer term is a common sweetener to encourage the initial exercise.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Newbridge Securities Corporation acted as the servicing agent for the Warrant Letters and will receive a fixed fee of $400,000 and expense reimbursement of up to $50,000.

Stakeholder Impact

• Shareholders: Experience immediate dilution from the exercise of existing warrants at a discounted price and potential future dilution from the exercise of newly issued warrants. However, the company gains immediate capital, which could support operations and strategic initiatives.
• Warrant Holders (Exercising): Benefited from a reduced exercise price for their existing warrants and received new warrants, potentially offering future upside.
• Company: Receives a crucial capital infusion to support its operations and potentially reduce short-term financial pressures.

Next Steps

• The transaction is expected to close on or about September 25, 2025.
• The company expects to enter into further Warrant Letters prior to the Closing Date.
• The company will release additional disclosure as to the final amounts of Outstanding Warrants exercised and the number of New Warrants issued.
• The company will use commercially reasonable efforts to register the resale of the shares of common stock underlying the New Warrants.

Key Dates

Recommendation

While the capital raise provides essential liquidity for Modular Medical, the terms involve significant dilution for existing shareholders due to the discounted exercise of prior warrants and the issuance of new warrants. This indicates a company in need of capital, and while the immediate cash is positive for stability, the long-term dilutive effect and the cost of financing suggest a 'hold' position rather than a 'buy' or 'sell' for a seasoned investor. The transaction stabilizes the company but at a notable cost to equity value.

Keywords

Modular Medical, MODD, Warrants, Equity Financing, Capital Raise, SEC Filing, Inducement Offer, Common Stock, Dilution, Nasdaq